OCUL

Ocular Therapeutix, Inc. · NASDAQ · Healthcare · USD · 10-K for 2025, filed 2026-02-05

Figures on this page computed 2026-11-08 13:13 UTC

Last close

7.14USD

Market data, 2026-11-04

OCUL: weekly closes from 9.16 on 2026-05-15 to 7.14 on 2026-11-04, a move of -22.1%. Prices in USD.

Weekly closes, 2026-05-15 to 2026-11-04

Over that span: -22.1%

Except where said otherwise: 10-K for 2025, filed 2026-02-05

n/aP/E
We do not hold this figure for this company, so there is nothing to place.
Price / Earnings per Share (diluted)
Source
computed
Fiscal year
2025
Accession
0001104659-26-010664
Reported in
USD
- computed
- 10-K for 2025, filed 2026-02-05
The filing itself
n/aROIC
We do not hold this figure for this company, so there is nothing to place.
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Fiscal year
2025
Accession
0001104659-26-010664
Reported in
USD
- 10-K for 2025, filed 2026-02-05
- 10-K for 2025, filed 2026-02-05
- 10-K for 2025, filed 2026-02-05
- 10-Q for 2025, filed 2026-08-03
- 10-K for 2025, filed 2026-02-05
- 10-Q for 2025, filed 2026-08-03
The filing itself
-511.9%Net margin
Net Income / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001104659-26-010664
Reported in
USD
- 10-K for 2025, filed 2026-02-05
- 10-K for 2025, filed 2026-02-05
The filing itself
-417.5%FCF margin
Free Cash Flow / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001104659-26-010664
Reported in
USD
- 10-K for 2025, filed 2026-02-05
- 10-K for 2025, filed 2026-02-05
The filing itself
0.12Debt/equity
Total Debt / Shareholders' Equity
Source
computed
Fiscal year
2025
Accession
0001104659-26-010664
Reported in
USD
- 10-K for 2025, filed 2026-02-05
- 10-Q for 2025, filed 2026-08-03
The filing itself
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed

Price is the furthest below its sector's middle: 0.27 against 0.38 on the market's range.

What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.

Five bars, one line

lens 7 of 9

1.75x

2.59x

2.58x

1.10x

0.95x

SalesProfitFree cash flowDebtPrice

Each bar against this company's own average; the line is that average.

Filed2025

Market data2026-11-04

Each against its own average

5 of 5 read

Except where said otherwise: 10-K for 2025, filed 2026-02-05

Sales1.75x
Its own average over 10 years, 29.7M.
Profit2.59x
Its own average over 10 years, -102.8M.
Free cash flow2.58x
Its own average over 10 years, -83.9M.
Debt1.10x
Its own average over 6 years, 69.8M.
Price0.95x
Its own average over 11 years, 8. Market data, 2026-11-04

Profit is furthest from its own average, at 2.59 times.

The filed years, as a table

Each line is 100 at 2016-12-31, the first year we hold.

Filed year	Sales	Shares in issue
2016-12-31	100.0	n/a
2017-12-31	101.9	n/a
2018-12-31	105.5	n/a
2019-12-31	224.0	100.0
2020-12-31	922.3	134.2
2021-12-31	2,306.4	181.5
2022-12-31	2,728.9	182.5
2023-12-31	3,097.1	189.1
2024-12-31	3,376.9	349.6
2025-12-31	2,753.1	413.6

How sales was got

Source: filed
Statement: income
Fiscal year: 2025
Accession: 0001104659-26-010664
Reported in: USD

The filing itself

How shares in issue was got

Source: filed
Statement: income
Fiscal year: 2025
Accession: 0001104659-26-010664
Reported in: USD

The filing itself

Figures behind the shape

Growth

24.4%

faster is higher, placed against 4,950 companies as of 2026-11-07

Five-year revenue growth rate24.4%
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed
Five-year EPS growth raten/a
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed
One-year change in net income-37.4%
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed

Returns on capital

-40.6%

higher is higher, placed against 5,089 companies as of 2026-11-07

Return on invested capitaln/a
We do not hold this figure for this company, so there is nothing to place.
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Fiscal year
2025
Accession
0001104659-26-010664
Reported in
USD
- 10-K for 2025, filed 2026-02-05
- 10-K for 2025, filed 2026-02-05
- 10-K for 2025, filed 2026-02-05
- 10-Q for 2025, filed 2026-08-03
- 10-K for 2025, filed 2026-02-05
- 10-Q for 2025, filed 2026-08-03
The filing itself
Return on equity-40.6%
Net Income / Shareholders' Equity x 100
Source
computed
Fiscal year
2025
Accession
0001104659-26-010664
Reported in
USD
- 10-K for 2025, filed 2026-02-05
- 10-Q for 2025, filed 2026-08-03
The filing itself
Return on assets-32.9%
Net Income / Total Assets x 100
Source
computed
Fiscal year
2025
Accession
0001104659-26-010664
Reported in
USD
- 10-K for 2025, filed 2026-02-05
- 10-Q for 2025, filed 2026-08-03
The filing itself

Margins

87.3%

wider is higher, placed against 3,412 companies as of 2026-11-07

Gross margin87.3%
Gross Profit / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001104659-26-010664
Reported in
USD
- 10-K for 2025, filed 2026-02-05
- 10-K for 2025, filed 2026-02-05
The filing itself
Operating margin-519.8%
Operating Income / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001104659-26-010664
Reported in
USD
- 10-K for 2025, filed 2026-02-05
- 10-K for 2025, filed 2026-02-05
The filing itself
Net margin-511.9%
Net Income / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001104659-26-010664
Reported in
USD
- 10-K for 2025, filed 2026-02-05
- 10-K for 2025, filed 2026-02-05
The filing itself
Free cash flow margin-417.5%
Free Cash Flow / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001104659-26-010664
Reported in
USD
- 10-K for 2025, filed 2026-02-05
- 10-K for 2025, filed 2026-02-05
The filing itself

Price

1.9x

cheaper is higher, placed against 4,362 companies as of 2026-11-07

Price to earningsn/a
We do not hold this figure for this company, so there is nothing to place.
Price / Earnings per Share (diluted)
Source
computed
Fiscal year
2025
Accession
0001104659-26-010664
Reported in
USD
- computed
- 10-K for 2025, filed 2026-02-05
The filing itself
Price to book1.9x10-Q for 2025, filed 2026-08-03
Price / Book Value per Share, where BVPS = Shareholders' Equity / Diluted Shares
Source
computed
Fiscal year
2025
Accession
0001104659-26-089450
Reported in
USD
- computed
- 10-Q for 2025, filed 2026-08-03
- computed
- 10-K for 2025, filed 2026-02-05
The filing itself
EV to EBITDAn/a
We do not hold this figure for this company, so there is nothing to place.
Enterprise Value / EBITDA, where EV = Market Cap + Total Debt - Cash
Source
computed
Fiscal year
2025
Accession
0001104659-26-010664
Reported in
USD
- computed
- 10-K for 2025, filed 2026-02-05
- 10-K for 2025, filed 2026-02-05
- 10-Q for 2025, filed 2026-08-03
- 10-K for 2025, filed 2026-02-05
The filing itself
Price to sales ratio23.8x
Market Cap / Revenue, where Market Cap = Price x Diluted Shares
Source
computed
Fiscal year
2025
Accession
0001104659-26-010664
Reported in
USD
- computed
- 10-K for 2025, filed 2026-02-05
- 10-K for 2025, filed 2026-02-05
The filing itself

Safety

0.12

safer is higher, placed against 3,227 companies as of 2026-11-07

Debt to equity0.12
Total Debt / Shareholders' Equity
Source
computed
Fiscal year
2025
Accession
0001104659-26-010664
Reported in
USD
- 10-K for 2025, filed 2026-02-05
- 10-Q for 2025, filed 2026-08-03
The filing itself
Current ratio15.3910-Q for 2025, filed 2026-08-03
Current Assets / Current Liabilities
Source
computed
Fiscal year
2025
Accession
0001104659-26-089450
Reported in
USD
- 10-Q for 2025, filed 2026-08-03
- 10-Q for 2025, filed 2026-08-03
The filing itself
Interest coveragen/a
We do not hold this figure for this company, so there is nothing to place.
Operating Income / Interest Expense
Source
computed
Fiscal year
2025
Accession
0001104659-26-010664
Reported in
USD
- 10-K for 2025, filed 2026-02-05
- 10-K for 2025, filed 2026-02-05
The filing itself
Altman Z-Score2.86
1.2 x A + 1.4 x B + 3.3 x C + 0.6 x D + 1.0 x E (A=WC/TA, B=RE/TA, C=EBIT/TA, D=MktCap/TL, E=Rev/TA)
Source
computed
Taken on
2026-11-07
Reported in
USD
- Computed from the 10-K for 2025, filed 2026-02-05
- Computed from the 10-K for 2025, filed 2026-02-05
- Computed from the 10-K for 2025, filed 2026-02-05
- Computed from the 10-K for 2025, filed 2026-02-05
- Computed from the 10-K for 2025, filed 2026-02-05

What it pays out

n/a

We do not hold this figure for this company, so there is nothing to place.

more, and better covered, is higher, with no cohort held

Dividend yieldn/a
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed
Payout ration/a
We do not hold this figure for this company, so there is nothing to place.
Common Dividends Paid / Net Income x 100, both from the latest filed fiscal year
Source
computed
Fiscal year
2025
Accession
0001104659-26-010664
Reported in
USD
- 10-K for 2025, filed 2026-02-05
- Computed from the 10-K for 2025, filed 2026-02-05
- 10-K for 2025, filed 2026-02-05
The filing itself
Dividend cover ration/a
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed

Share a finding

A link to the finding, not to you: it carries nothing about your account.